Impact of positron emission tomography with FDG-PET in treatment of patients with suspected recurrent ovarian cancer;Impacto de la tomografía por emisión de positrones mediante 18-Fluoro-2-Desoxi-D-Glucosa (PET-FDG) en el manejo terapéutico de pacientes con recurrencia secundaria a cáncer de ovario

Revista Espanola de Medicina Nuclear

Volumn 24, Issue 2, 2005, Pages 113-126

  Ruiz Hernandez G ^a   Delgado Bolton, R C ^a   Fernandez Perez C ^b   Lapena L ^b   Jimenez Vicioso A ^a   Perez Castejon Ma J ^a   Domper, M ^a   Montz, R ^a   Carreras Delgado, J L ^b  

^a Instituto PET Focuscan   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

FDG PET; Impact on management; Recurrent ovarian cancer

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; TREATMENT PLANNING;

EID: 16244409503     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13071687     Document Type: Article

References (38)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. En: De Vita Jr. VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins 2001;2:1597-632.
3. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002;7:20-8.
4. Vaidya AP, Curtin JP. The follow-up of ovarian cancer. Semin Oncol 2003;30:401-12.
5. Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, Czernin J, et al. PET in Oncology: will it replace the other modalities? Semin Nucl Med 1997;27:94-106.
6. Brock CS, Meikle SR, Price P. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? Eur J Nucl Med 1997;24:691-705.
7. Bar-Shalom R, Valdivia AY, Blaufox MD. PET Imaging in Oncology. Semin Nucl Med 2000;15:150-85.
8. Mijnhout GS, Hooft L, van Tulder MW, Deville WL, Teule GJ, Hoekstra OS. How to perform a comprehensive search for FDG-PET literature. Eur J Nucl Med 2000;27:91-7.
9. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001;28:1707-23.
10. Fenchel S, Grab D, Nuessle K, Kotzerke J, Rieber A, Kreienberg R, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology2002;223:780-8.
11. Rieber A, Nussle K, Stohr I, Grab D, Fenchel S, Kreienberg R, et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol 2001;177:123-9.
12. Schroder W, Zimny M, Rudlowski C, Bull U, Rath W. The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer 1999;9:117-22.
13. Grab D, Flock F, Stohr I, Nussle K, Rieber A, Fenchel S, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000;77:454-9.
14. Kubik-Huch RA, Dorffler W, von Schulthess GK, Marincek B, Kochli OR, Seifert B, et al. Value of (18 F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10:761-7.
15. Karlan BY, Hawkins R, Hoh C, Lee M, Tse N, Cane P, et al. Whole-body positron emission tomography with 2-18F-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993;51:175-81.
16. Yuan CC, Liu RS, Wang PH, Ng HT, Yeh SH. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting ovarian carcinoma. Initial report. J Reprod Med 1999;44:775-8.
17. Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 2002;85:53-8.
18. Bristow RE, Simpkins F, Pannu HK, Fishman EK, Montz FJ. Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer. Gynecol Oncol 2002;85:196-200.
19. Zimny M, Siggelkow W, Schroder W, Nowak B, Biemann S, Rath W, et al. 2-(Fluorine-18)-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001;83:310-5.
20. Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. Am J Roentgenol 2001;176:1449-54.
21. Yen RF, Sun SS, Shen YY, Changlai SP, Kao A. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001;21:3691-4.
22. Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging 2002;29:797-803.
23. Chang WC, Hung YC, Kao CH, Yen RF, Shen YY, Lin CC. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker. Neoplasma 2002;49:329-33.
24. García Velloso MJ, Boán García JF, Villar Luque LM, Aramendia Beitia JM, López García G, Richter Echeverría JA. Tomografía por emisión de positrones con F-18-FDG en el diagnostico de recurrencia del cancer de ovario. Comparación con TAC y CA 125. Rev Esp Med Nucl 2003;22:217-23.
25. Picchio M, Sironi S, Messa C, Mangili G, Landoni C, Gianolli L, et al. Advanced ovarian carcinoma: usefulness of 18F FDG-PET in combination with CT for lesion detection after primary treatment. Q J Nucl Med 2003;47:77-84.
26. Schelbert HR, Hoh CK, Royal HD, Brown M, Dahlbom MN, Dehdashti F, et al. Procedure guideline for tumor imaging using Fluorine-18-FDG. J Nucl Med 1998;39:1302-5.
27. Avril N, Dose J, Janicke F, Sense S, Ziegler S, Laubenbacher C, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848-57.
28. Ho CL, Dehdashti F, Griffeth LK, Buse PE, Balfe DM, Siegel BA. FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr 1996;20:363-9.
29. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130-9.
30. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991;11:88-94.
31. Hicks RJ, Kalff V, MacManus MP, Ware RE, McKenzie AF, Matthews JP, et al. The utility of 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001;42:1605-13.
32. Hicks RJ, Kalff V, MacManus MP, Ware RE, Hogg A, McKenzie AF, et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001;42:1596-1604.
33. Cho SM, Ha HK, Byun JY, Lee JM, Kim CJ, Nam-Koong SE, et al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR Am J Roentgenol 2002;179:391-5.
34. Menzel C, Dobert N, Hamscho N, Zaplatnikov K, Vasvatekis S, Matic V, et al. The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strahlenther Onkol 2004;180:497-501.
35. Kim S, Chung JK, Kang SB, Kim MH, Jeong JM, Lee DS, et al. (18F) FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging 2004;31:196-201.
36. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. Am J Roentgenol 2000;174:1005-8.
37. Kent DL, Larson EB. Disease, level of impact, and quality of research methods: Three dimensions of clinical efficacy assessment applied to magnetic resonance imaging. Invest Radiol 1992;27:245-54.
38. Thornbury JR, Kido DK, Mushlin AI, Phelps CE, Mooney C, Fryback DG. Increasing the scientific quality of clinical efficacy studies of magnetic resonance imaging. Invest Radiol 1991;26:829-35.